Innoscripta SE Reports Strong First Quarter Growth

Innoscripta SE has announced robust financial results for the first quarter of 2026. The company reported a revenue increase to EUR 40.3 million, up from EUR 25.6 million during the same period last year. Additionally, EBIT rose significantly to EUR 27.3 million from EUR 16.3 million, resulting in an enhanced EBIT margin of 67.7%, compared to 63.7% the previous year.

The company's cost management strategies and scalable business model played key roles in outpacing revenue growth relative to administrative and marketing expenses. Innoscripta continues to enhance its Clusterix platform while expanding internationally and acquiring new customers.

The German R&D tax incentive changes in early 2026, including an increased assessment base and a surcharge on eligible expenses, are expected to further boost the program's appeal, setting positive expectations for continued growth.